Awaiting trial results, Sangamo pushes on with zinc finger technology

Sangamo BioSciences Inc. 's gene-editing technology could produce exciting commercial news on the horizon. But the Richmond company isn't resting on what may happen — it continues to gather scientific evidence around the technology.
The zinc finger technology has been described as a kind of "molecular scissors" that cuts and replaces pieces of a gene. So instead of treating a disease, Sangamo's work could provide a functional cure for some big-name diseases like AIDS and hemophilia.
Talk like that puts Richmond-based Sangamo (NASDAQ: SGMO) dead-center in the targets of potential investors and of doubters, too.